February, 2022: Research article: Tacrolimus-resistant SARS-CoV-2-specific T cell products to prevent and treat severe COVID-19 in immunosuppressed patients
Peter, L., Wendering, D. J., Schlickeiser, S., Hoffmann, H., Noster, R., Wagner, D. L., Zarrinrad, G., Münch, S., Picht, S., Schulenberg, S., Moradian, H., Mashreghi, M. F., Klein, O., Gossen, M., Roch, T., Babel, N., Reinke, P., Volk, H. D., Amini, L., & Schmueck-Henneresse, M. (2022). Tacrolimus-resistant SARS-CoV-2-specific T-cell products to prevent and treat severe COVID-19 in immunosuppressed patients. Molecular Therapy - Methods and Clinical Development, 25(June), 52–73. https://doi.org/10.1016/j.omtm.2022.02.012